5276 - 5300 of 8808 Results
Title
Year
-
OPENTitle: Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP)Journal Name: Frontiers in Aging NeurosciencePublisher: Frontiers Media SAVol: 12Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnagi.2020.553635Best OA location URL: https://escholarship.org/uc/item/46x4b7c2Citation Count: 33
-
OPENTitle: Treatment Stratification of Patients with Metastatic Castration-Resistant Prostate Cancer by Machine LearningJournal Name: iSciencePublisher: Elsevier BVVol: 23Issue #: 2Start Page: 100804End Page: 100804Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.isci.2019.100804Best OA location URL: https://doi.org/10.1016/j.isci.2019.100804Citation Count: 19
- Kinesthetic Cells within the Subthalamic Nucleus and Deep Brain Stimulation for Parkinson Disease2020OPENTitle: Kinesthetic Cells within the Subthalamic Nucleus and Deep Brain Stimulation for Parkinson DiseaseJournal Name: World NeurosurgeryPublisher: Elsevier BVVol: 139Issue #:Start Page: e784End Page: e791Publication Date:Open Access(OA) Status: OPENLicense: publisher-specific-oaDOI - Digital Object Identifier: 10.1016/j.wneu.2020.04.160Best OA location URL: https://www.sciencedirect.com/science/article/am/pii/S187887502030869XCitation Count: 2
-
RESTRICTEDTitle: Stem-Cell Research of Parkinson Disease: Bibliometric Analysis of Research Productivity from 1999 to 2018Journal Name: World NeurosurgeryPublisher: Elsevier BVVol: 134Issue #:Start Page: e405End Page: e411Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.wneu.2019.10.087Citation Count: 13
-
OPENTitle: Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeysJournal Name: eBioMedicinePublisher: Elsevier BVVol: 59Issue #:Start Page: 102944End Page: 102944Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.ebiom.2020.102944Best OA location URL: http://www.thelancet.com/article/S2352396420303200/pdfCitation Count: 63
-
OPENTitle: Not only loud but also intelligibleJournal Name: eClinicalMedicinePublisher: Elsevier BVVol: 24Issue #:Start Page: 100456End Page: 100456Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.eclinm.2020.100456Best OA location URL: http://www.thelancet.com/article/S2589537020302005/pdfCitation Count: 2
-
OPENTitle: The Nrf2-mediated defense mechanism associated with HFE genotype limits vulnerability to oxidative stress-induced toxicityJournal Name: ToxicologyPublisher: Elsevier BVVol: 441Issue #:Start Page: 152525End Page: 152525Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.tox.2020.152525Best OA location URL: https://scholarsphere.psu.edu/resources/0165b409-31f0-464c-9424-715ab3ca7de4Citation Count: 13
-
OPENTitle: Provisional case definitions for COVID-19-associated neurological diseaseJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 19Issue #: 11Start Page: 890End Page: 891Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30373-2Best OA location URL: http://www.thelancet.com/article/S1474442220303732/pdfCitation Count: 7
-
RESTRICTEDTitle: Patient-centred management of Parkinson's diseaseJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 19Issue #: 11Start Page: 888End Page: 889Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30355-0Citation Count: 0
-
OPENTitle: Huntington's disease in BangladeshJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 19Issue #: 8Start Page: 644End Page: 645Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30216-7Best OA location URL: http://www.thelancet.com/article/S1474442220302167/pdfCitation Count: 1
-
OPENTitle: Long before Huntington's disease: what matters most?Journal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 19Issue #: 6Start Page: 473End Page: 475Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/s1474-4422(20)30156-3Best OA location URL: http://www.thelancet.com/article/S1474442220301563/pdfCitation Count: 0
-
OPENTitle: A cornerstone initiative for progress in Parkinson's diseaseJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 19Issue #: 1Start Page: 1End Page: 1Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(19)30432-6Best OA location URL: http://www.thelancet.com/article/S1474442219304326/pdfCitation Count: 1
-
OPENTitle: Increased striatal dopamine in carriers of GBA mutations: compensation or epiphenomenon?Journal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 19Issue #: 1Start Page: 27End Page: 29Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(19)30355-2Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/6924570Citation Count: 1
-
RESTRICTEDTitle: Developing therapies for Parkinson's diseaseJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 19Issue #: 10Start Page: 797End Page: 797Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30320-3Best OA location URL: http://www.thelancet.com/article/S1474442220303203/pdfCitation Count: 5
-
RESTRICTEDTitle: Multiple sclerosis in 2019: predicting progressionJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 19Issue #: 1Start Page: 12End Page: 14Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(19)30441-7Citation Count: 1
-
RESTRICTEDTitle: Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled studyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 19Issue #: 6Start Page: 491End Page: 501Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30108-3Citation Count: 129
-
RESTRICTEDTitle: Movement disorders in 2019: from antibodies to lifestyle interventionsJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 19Issue #: 1Start Page: 10End Page: 12Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(19)30438-7Best OA location URL: https://resolver.sub.uni-goettingen.de/purl?gro-2/133486Citation Count: 1
-
OPENTitle: Annual Prevalence of Use of Potentially Inappropriate Medications for Treatment of Affective Disorders in Parkinson's DiseaseJournal Name: The American Journal of Geriatric PsychiatryPublisher: Elsevier BVVol: 29Issue #: 1Start Page: 35End Page: 47Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.jagp.2020.05.014Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/7671949Citation Count: 5
-
OPENTitle: Transdifferentiation of Mouse Embryonic Fibroblasts into Dopaminergic Neurons Reactivates LINE-1 Repetitive ElementsJournal Name: Stem Cell ReportsPublisher: Elsevier BVVol: 14Issue #: 1Start Page: 60End Page: 74Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.stemcr.2019.12.002Best OA location URL: http://www.cell.com/article/S2213671119304163/pdfCitation Count: 23
-
RESTRICTEDTitle: Neural activity in functional movement disorders after inpatient rehabilitationJournal Name: Psychiatry Research: NeuroimagingPublisher: Elsevier BVVol: 303Issue #:Start Page: 111125End Page: 111125Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.pscychresns.2020.111125Citation Count: 27
-
RESTRICTEDTitle: Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 studyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 19Issue #: 2Start Page: 135End Page: 144Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(19)30396-5Citation Count: 112
-
RESTRICTEDTitle: Getting ahead in the race for a cure: How nonprofits are financing biomedical R&DJournal Name: Research PolicyPublisher: Elsevier BVVol: 49Issue #: 8Start Page: 104032End Page: 104032Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.respol.2020.104032Citation Count: 4
-
RESTRICTEDTitle: Characteristics, treatment patterns and disease burden of people with Parkinson's disease in the Parkinson's disease real-world impact assessment (PRISM) studyJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 79Issue #:Start Page: e86End Page: e86Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.06.312Citation Count: 0
-
RESTRICTEDTitle: Does increased forefoot load contribute to freezing of gait in Parkinson's disease? A clinical observationJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 77Issue #:Start Page: 83End Page: 84Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.06.021Citation Count: 1
-
OPENTitle: Analysis of heterozygous PRKN variants and copy number variations in Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 79Issue #:Start Page: e28End Page: e28Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.06.123Citation Count: 6